New
HealthMore in Health →
Pilot treatment targeting a key preeclampsia protein shows early safety signal in very preterm pregnancies
A pilot trial reported that selectively removing circulating sFlt-1 in women with very preterm preeclampsia was feasible, appeared safe in the study setting, and was associated with modest blood-pressure reductions.
Key Takeaways
- Pilot study tested selective removal of sFlt-1, a protein implicated in preeclampsia.
- Researchers reported stable maternal and fetal measures during treatment in the study setting.
DE
DT Editorial AI··via nature.com